TMCnet News
Entasis Therapeutics to Participate in A.G.P.'s Virtual Healthcare SymposiumWALTHAM, Mass., Nov. 17, 2020 (GLOBE NEWSWIRE) -- Entasis Therapeutics Holdings Inc. (NASDAQ: ETTX), a clinical-stage biopharmaceutical company focused on the discovery and development of novel antibacterial products, today announced that members of management will participate in A.G.P.’s Virtual Healthcare Symposium on Thursday, November 19th, 2020. The event will consist of 1-on-1 virtual investor meetings. Investors attending the conference virtually who are interested in meeting with Company management should contact their A.G.P. representative. About Entasis Entasis is a clinical-stage bioparmaceutical company focused on the discovery, development and commercialization of novel antibacterial products to treat serious infections caused by multidrug-resistant Gram-negative bacteria. Entasis’ pathogen-targeted design platform has produced a pipeline of product candidates, including sulbactam-durlobactam (targeting Acinetobacter baumannii infections), zoliflodacin (targeting Neisseria gonorrhoeae infections), ETX0282CPDP (targeting Enterobacteriaceae infections) and ETX0462 (targeting Pseudomonas infections). For more information, visit www.entasistx.com. Entasis Company Contact Investor Relations Contact Media Contact
|
